Replies to post #223464 on Biotech Values

[biotech_researcher]

Jbog, I expect (and hope) Dan Brown will be under tremendous pressure to sell his best-in-class botulism asset company and reap his reward early. Otherwise, we and he will be in for a lot of dilution and a long slog. They could add six more trials right now if they had the resources..

[biotech2020]

I think partnering would be helpful for near term price support, but Revance has significant upside regardless of whether they partner or go it alone. The real advantage they have is a best in class product in a fast growing market. They have enough cash to get through approval, and I don't think significant dilution would be required for commercialization. They shouldn't need a large sales force for the aesthetic market if they get the 6 month label. I took advantage of the recent selloff to add to my already oversized position.

[jmkobers]

<<As of today my best guess is that they will, and in that case the only people to profit will be the insiders>>

Jbog:

One thing I wonder about is the participants in the latest offering. Surely they are aware of the risks of the go it alone strategy and undoubtedly asked Browne about it. They are in it to make money after all. Whats' your take on that? Could they make their money either way?

Also, lately you have been considering buying shares of RVNC which, if you believe the above, wouldn't make sense. Browne hasn't changed his behavior recently in regards to being a seller vs. a buyer so why did you think it could be a good investment recently and today doubt it?